MONTREAL, Sept. 15 /CNW/ - Lively discussions on the most pressing topics in men's health will highlight the 4th C2 Academic Retreat (C2R) being organized jointly by the Canadian Urologic Oncology Group (CUOG) and the Canadian Urology Research Consortium (CURC) scheduled for the weekend of September 25 to 27, 2009 at the W Hotel in Montreal.
Accredited by The Royal College of Physicians and Surgeons of Canada, this three-day educational event will include provocative "Town Hall" sessions on the topics of Hormone Replacement and Cancer Risk, Prostrate Screening Controversies and the use of Robotic Technology in Surgery (Is it ready for prime time?).
"The line-up of topics and the caliber of presenters is unsurpassed in all the years we have been conducting these events," notes Dr. Laurence Klotz, Chair of the CURC and immediate past president of the Canadian Urology Association (CUA).
Visiting presenters will include Dr. Eric Klein, Head of Urologic Oncology in the Urological Institute at Cleveland Clinic and editor of Urology; Dr. Christopher Evans, Chair, Department of Urology, UC Davis Cancer Center in Sacramento; and Anthony Zietman, Professor of Radiation Oncology at Harvard, and a world leader in prostate cancer radiation treatment.
Joining the discussion will be Canadian Broadcasting Corporation's Health Specialist Maureen Taylor, adding the voice of the public perception of men's health issues to the prostrate screening debate.
The C2R Retreat hosts 50 leading urologists, and kicks off at 7 PM on Friday September 25th with a Clinical Cases Conference, followed by industry presentations on Saturday, September 26th along with the Town Hall Debates. The event continues on Sunday morning with a point-counterpoint on robotic surgery in Canada.
The Retreat is especially unique as it allows the sponsoring (and often competing) pharmaceutical companies (i.e. Amgen AstraZeneca, Sanofi Aventis, GlaxoSmitKline, Merck Frosst, Novartis, Minoque Medical, Genesis Genomics, and Pfizer) to actively participate in the academic portion of the agenda.
"We strive to ensure that the intellectual content of C2R continues to be solid, medically provocative, controversial, and of great interest to our delegates - Men's Health is very topical, and because of this, the Urological Community will always be curious about what's around the corner, what we can learn from each other and what we can do better if not differently," says Klotz.
Canadian Urology Research Consortium
The Canadian Urology Research Consortium (CURC) is a clinical research investigator network comprised of leading academic and community-based urologists committed to furthering urology research in Canada including pharmaceutical trials.
Canadian Urologic Oncology Group
The Canadian Urologic Oncology Group (CUOG) is a clinical research investigator network of leading academic and community-based urologists, medical oncologists and radiation oncologists, committed to furthering urology research in Canada. A non-profit, non-share corporation, CUOG has a cooperative relationship with the Canadian Urology Association (CUA), and partners with the Canadian Urology Research Consortium (CURC) with respect to mutually held oncology studies.
In their mutual quest to bring effective treatments to market, the CURC and CUOG pursue investigator initiated and pharmaceutical sponsored clinical trials to evaluate drugs and technologies for urological disorders such as: prostate disease (including cancer, BPH, and prostatitis), erectile dysfunction, overactive bladder, incontinence and infection. Further information can be found at: www.curc.ca and www.cuog.org
SOURCE PATTY DJAN INC.
For further information: For further information: Dr. Laurence Klotz, MD, Chair CURC, Laurence.Klotz@sunnybrook.ca, Tel: (416) 480-4788; Dr. Fred Saad, MD, Chair CUOG, email@example.com, Tel: (514) 890-8000 ext 27466; Public Relations: Patty Djan Inc., firstname.lastname@example.org, Tel: (416) 656-3528